Celldex Therapeutics Inc. (NASDAQ: CLDX) announced the pricing of an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, according to a company statement.

The biotechnology company expects to receive approximately $300 million in gross proceeds from the offering, excluding underwriting discounts, commissions and other expenses. Celldex has granted underwriters a 30-day option to purchase up to an additional 1,551,750 shares at the public offering price, less underwriting fees.

The offering is expected to close on or about April 6, 2026, subject to customary closing conditions.

Celldex stated it intends to use the net proceeds along with existing cash and securities to fund commercial readiness activities for barzolvolimab, continue clinical and preclinical development of product candidates, grow its bispecific antibody platform, develop additional pipeline candidates and for general corporate purposes.

Leerink Partners, TD Cowen, Guggenheim Securities and Cantor are serving as joint bookrunning managers for the offering. LifeSci Capital and H.C. Wainwright & Co. are acting as co-lead managers.

The offering is being conducted under a shelf registration statement on Form S-3 that became effective in November 2023. The Hampton, New Jersey-based company describes itself as a clinical-stage biotechnology company focused on mast cell biology and developing therapeutics for inflammatory, allergic and autoimmune diseases.